Celltrion pursues 270 billion won share acquisition to resolve undervaluation

South Korean biopharmaceutical company Celltrion is initiating a significant share acquisition plan valued at approximately 270 billion won (about $195 million USD). This move is designed to bolster shareholder value and reinforce the company's commitment to responsible management.

The comprehensive plan involves multiple strategies. Celltrion intends to repurchase its own treasury stock and facilitate the acquisition of shares through employee stock ownership plans. Additionally, the largest shareholder group is expected to participate by purchasing shares, further consolidating the company's ownership structure and signaling confidence in its future prospects.

Celltrion formally announced these initiatives to its shareholders via its official website on the 5th. The company stated that these measures are being pursued following the completion of procedures related to a bonus share issuance. The overarching goal is to enhance the company's overall corporate value and address any potential undervaluation in the market.

This strategic share acquisition underscores Celltrion's focus on improving its financial standing and demonstrating a commitment to its investors. By actively managing its share structure and increasing investment from key stakeholders, the company aims to create a more robust and appealing investment profile.